Marciann Harris, NP
Nurse Practitioner · Wellington, CONPI 1053393421
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,000 of the $17,659 with a category attached, or 96.3%. Johnson & Johnson accounts for 96.3% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $17,271 and has fallen 99.5% since, to $90 in 2025. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $519.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$17K
- Pfizer$105
- Novo Nordisk$71
- Alkermes, Inc.$63
- Lilly USA, LLC$56
- GSK$56
- plus $309 from 13 others
What the payments were for
- Speaking & faculty fees$17,00096%
- Food & beverage$6594%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $17,000 |
| Pfizer | 2 | $105 |
| Novo Nordisk | 4 | $71 |
| Alkermes, Inc. | 1 | $63 |
| Lilly USA, LLC | 4 | $56 |
| GSK | 3 | $56 |
| AstraZeneca | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Novartis | 2 | $34 |
| Corium, LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Edwards Lifesciences | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Exact Sciences | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
How this compares
$17,659 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $32,234 |
| OzempicSemaglutide | 30 | $30,243 |
| JardianceEmpagliflozin | 32 | $29,932 |
| TrulicityDulaglutide | 19 | $19,268 |
| JanuviaSitagliptin Phosphate | 26 | $19,123 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,097 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,922 |
| SynthroidLevothyroxine Sodium | 19 | $2,023 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,812 |
| Atorvastatin Calcium | 167 | $1,795 |
| Levothyroxine Sodium | 167 | $1,673 |
| Pregabalin | 15 | $1,496 |
| Losartan Potassium | 154 | $1,419 |
| Metoprolol Succinate | 85 | $1,305 |
| Omeprazole | 90 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $105 | $32,23430 claims |
| Novo NordiskOzempic | $71 | $30,24330 claims |
| Boehringer IngelheimJardiance | $21 | $29,93232 claims |
| Lilly USA, LLCTrulicity | $56 | $19,26819 claims |
| GSKBreo Ellipta | $56 | $13,09725 claims |
| AstraZenecaSymbicort | $39 | $6,92225 claims |
| AbbVieSynthroid | $12 | $2,02319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Wellington
- Deborah HinnenColorado Springs$388K
- Christina HansonLone Tree$381K
- Kara HartPueblo$142K
- Amy SidorskiAurora$97K
- Lori WenzGrand Junction$54K
- Lisa KeithColorado Springs$52K
- Victoria SegroEnglewood$29K
- Christina ProulxDenver$28K
- Jose Diaz LeoDenver$24K
- Lolanda McBrideDenver$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.